Critical Care Medicine
Effect of Hyperoxia on Resuscitation of Experimental Combined Traumatic Brain Injury and Hemorrhagic Shock in Mice
Blasiole, Brian M.D., Ph.D.*; Bayr, Hülya M.D.†ı; Vagni, Vincent A. B.S.‡; Janesko-Feldman, Keri B.S.‡; Cheikhi, Amin B.S.§; Wisniewski, Stephen R. Ph.D.║; Long, Joseph B. Ph.D.#; Atkins, James M.D., Ph.D.**; Kagan, Valerian Ph.D.║; Kochanek, Patrick M. M.D., M.C.C.M.††
Background: Hypotension and hypoxemia worsen traumatic brain injury outcomes. Hyperoxic resuscitation is controversial. The authors proposed that hyperoxia would improve hemodynamics and neuronal survival by augmenting oxygen delivery despite increased oxidative stress and neuroinflammation in experimental combined controlled cortical impact plus hemorrhagic shock in mice.
Methods: Adult C57BL6 mice received controlled cortical impact followed by 35 min of hemorrhagic shock (mean arterial pressure, 25–27 mmHg). The resuscitation phase consisted of lactated Ringer’s boluses titrated to mean arterial pressure greater than 70 mmHg. Definitive care included returning shed blood. Either oxygen or room air was administered during the resuscitation phases. Brain tissue levels of oxidative stress and inflammatory markers were measured at 24 h and hippocampal neuronal survival was quantified at 7 days.
Results: Hyperoxia markedly increased brain tissue oxygen tension approximately four- to fivefold (n = 8) and reduced resuscitation fluid requirements approximately 15% (n = 53; both P < 0.05). Systemic and cerebral physiologic variables were not significantly affected by hyperoxia. Hippocampal neuron survival was approximately 40% greater with oxygen versus room air (n = 18, P = 0.03). However, ascorbate depletion doubled with oxygen versus room air (n = 11, P < 0.05). Brain tissue cytokines and chemokines were increased approximately 2- to 20-fold (n = 10) after combined controlled cortical impact injury plus hemorrhagic shock, whereas hyperoxia shifted cytokines toward a proinflammatory profile.
Conclusions: Hyperoxic resuscitation of cortical impact plus hemorrhagic shock reduced fluid requirements and increased brain tissue oxygen tension and hippocampal neuronal survival but exacerbated ascorbate depletion and neuroinflammation. The benefits of enhanced oxygen delivery during resuscitation of traumatic brain injury may outweigh detrimental increases in oxidative stress and neuroinflammation.
What We Already Know about This Topic
* Although hypoxemia worsens outcomes after traumatic brain injury, hyperoxic resuscitation is controversial
What This Article Tells Us That Is New
* In a model of combined traumatic brain injury and hemorrhagic shock, despite the observation of exacerbated ascorbate depletion and neuroinflammation, hyperoxic resuscitation increased brain tissue oxygen tension and hippocampal neuronal survival
NEUROLOGIC deficits following traumatic brain injury (TBI) are caused by the primary mechanical injury and subsequent cascade of biochemical, metabolic, and cellular derangements encompassing the secondary injury. In civilian and military settings, TBI is often seen not in isolation but in combination with other insults (polytrauma) that exaggerate the secondary injury.1
The occurrence of hypotension is associated with doubled mortality and worsened morbidity after TBI.3
Coupled with reduced cerebral blood flow acutely following TBI,4–6
hemorrhagic hypotension likely exacerbates cerebral hypoxia.7
Sustained brain tissue oxygen tension (PbtO2
) levels less than 15 mmHg or a PbtO2
less than 6 mmHg for any period of time following TBI is associated with increased mortality.9
Administration of supplemental oxygen after TBI in an attempt to improve oxygenation of vulnerable brain tissue in various settings has been used clinically with mixed results.10–13
In the setting of TBI with superimposed hemorrhagic shock (HS), however, it is unknown whether administration of supplemental oxygen improves resuscitation and outcomes.
Varying the fraction of inspired oxygen after different types of brain injury is currently under intense debate.14
Hyperoxic resuscitation of a focal cerebral injury has been shown to be neuroprotective in experimental studies by improving penumbral blood flow and maintaining penumbral oxygenation, decreasing infarct size, and ultimately improving outcomes.15–20
In clinical stroke studies, early application of normobaric hyperoxia increased magnetic resonance imaging evidence of aerobic metabolism and neuronal stability as well as transient clinical improvement.21
At the other end of the spectrum, however, the ischemia–reperfusion injury that occurs from administration of 100% oxygen on return of spontaneous circulation after cardiac arrest could be detrimental, particularly with regard to neurologic outcomes.23
Kilgannon et al.
recently showed arterial hyperoxia to be an independent predictor of in-hospital mortality after resuscitation from cardiac arrest.24
The surge of reactive oxygen species upon hyperoxic reperfusion leads to neuronal death from damaging lipid and protein peroxidation, impaired mitochondrial oxidative metabolism, and activation of cellular inflammation.25
The effect of hyperoxia on neurologic outcomes after TBI may be similar to a focal cerebral insult; although the mechanically disrupted brain is likely unsalvageable, the surrounding vulnerable tissue may benefit from hyperoxia in the face of reduced cerebral blood flow and altered cerebral hemodynamics.11
The combination of TBI and HS that occurs after polytrauma may represent a unique scenario with regard to the use of oxygen because the insult includes both TBI, which may be favorably influenced by supplemental oxygen, and the damaging effects of ischemia–reperfusion. We have developed and previously characterized a unique mouse model of controlled cortical impact (CCI) coupled with a brief, severe, pressure-controlled HS with a clinically relevant mean arterial pressure (MAP)-targeted resuscitation permitting study of acute systemic and cerebral physiology, neuropathology, and long-term functional outcomes.27
We sought to determine whether treatment with oxygen versus
room air (RA) influenced resuscitation and neuropathologic outcome in our combined CCI and HS mouse model. In this article, we present results showing that hyperoxia versus
RA improved cerebral hemodynamics and CA3 hippocampal neuron survival but resulted in worsened oxidative stress and neuroinflammation.
Materials and Methods
Experimental Protocol for In Vivo Studies
The Institutional Animal Care and Use Committee of the University of Pittsburgh approved all experiments. Adult (12–15 weeks of age) C57BL6 male mice (Jackson Laboratories, Bar Harbor, ME) weighing 27.7 ± 0.5 g were housed in controlled environmental conditions and allowed ad libitum
access to food and water until the start of the study. We used our established mouse combined CCI plus HS model as described by Hemerka et al.27
with four experimental groups: sham RA (burr hole, brain temperature probe, catheters, anesthesia, RA during prehospital and hospital phases, but no CCI or HS), sham oxygenation (craniotomy, catheters, anesthesia, pure oxygen via
nose cone during prehospital and hospital phases, but no CCI or HS), combined CCI plus HS and RA (RA administered throughout protocol), or combined CCI plus HS and oxygenation (pure oxygen via
nose cone during prehospital and hospital phases). Naïve mice were also used for the various brain tissue measurements detailed below. Naïve mice were age-, sex-, and vendor-matched C57BL6 mice not exposed to any insult or therapy. Briefly, anesthesia was induced with isoflurane 4% in 2:1 N2
nose cone in spontaneous breathing mice. Maintenance of anesthesia for subsequent surgical procedures was with isoflurane 1.5% and in a 2:1 N2
mixture. Femoral arterial and venous catheter access (modified PE-50 tubing) was via
inguinal cutdown. Mice were placed in a stereotactic frame (David Kopf Instruments, Tujunga, CA), and a 5-mm left parietal craniotomy was performed using a dental drill with removal of bone flap. After craniotomy, anesthesia was decreased and maintained with 1% isoflurane in RA for a 10-min stabilization period. A mild to moderate CCI to the left parietal cortex was performed via
a pneumatic impactor (Bimba Manufacturing Co., Monee, IL) with a flat 3-mm tip at a velocity of 5 m/s to a depth of 1 mm. The craniotomy was closed by replacing the bone flap and sealing with dental cement. Next, a 35-min pressure-controlled hemorrhagic “shock” phase (MAP, 25 ± 2 mmHg) was initiated by withdrawing blood (2.3 ml/100 g; citrated for later reinfusion) over 5 min. Continued removal or reinfusion of the autologous blood via
the IV route in 0.05-ml aliquots was performed to rigorously maintain MAP of 25 ± 2 mmHg during the shock phase. The mice were allowed to spontaneously breathe 0.5% isoflurane in RA during this phase. Thirty-five minutes after CCI and HS (or at an equivalent anesthesia time point in the sham groups), spontaneously breathing mice were randomized to treatment with either oxygen (“hyperoxia”) or RA by nose cone administration upon entering the “prehospital” phase. Prehospital resuscitation consisted of an initial IV bolus of 20 ml/kg of lactated Ringer’s solution followed by maintenance lactated Ringer’s fluid at 4 ml kg-1
. Lactated Ringer’s boluses (10 ml/kg) were used every 5 min as needed to maintain MAP greater than 70 mmHg for the 90-min duration of prehospital resuscitation. The final “hospital” phase simulated definitive care by reinfusion of shed blood over 15 min, during which the experimental fraction of inspired oxygen was maintained and administered with 1% isoflurane. After this phase, the femoral catheters were removed, incisions were closed and infiltrated with bupivacaine 0.25% (0.05 cc), and the inhalational anesthetic was discontinued. Mice treated with oxygen were allowed to recover with supplemental oxygen, whereas those in the RA group were allowed to recover on RA. Both groups were returned to their cages after they were fully awake. Resuscitation fluid volumes administered in each phase of the experimental protocol were recorded.
MAP and heart rate were monitored continuously via the femoral arterial cannula and recorded at baseline; after CCI; and every 5 min during the shock, prehospital, and hospital phases in all mice. Intracranial pressure (ICP) was similarly monitored and recorded in select mice (n = 14 that were subsequently sacrificed for histologic assessment at 7 days after injury) using a 2-French ultra-miniature pressure transducer (SPR-407; Millar, Houston, TX) inserted into the right frontal cortex (contralateral to the CCI) through a burr hole. PbtO2 was also monitored and recorded in a separate group of mice (n = 8, not used for additional outcome studies) using a microelectrode (Unisense, 50 μm; Arhus, Denmark) stereotactically inserted via a burr hole through the cortex into the left dorsal hippocampus (ipsilateral to the CCI; bregma −2.5 AP, −2.0 ML; depth, 2.0 mm). Arterial blood gas measurements were obtained at baseline, at the end of the shock phase (35 min after CCI and HS), after the 90-min prehospital resuscitation (125 min after CCI and HS), and at the completion of the hospital phase (140 min after CCI and HS). Lactate, hematocrit, base deficit, and glucose values were recorded in conjunction with the arterial blood gas measurements (Stat Profile; Nova Biomedical, Waltham, MA). Temperature was monitored in the brain (via a separate burr hole in the right frontal lobe bone) and rectum, and brain temperature was controlled at 37.0 ± 0.5°C using a heat lamp throughout the experimental protocol.
Brain tissue samples were obtained at 24 h after CCI and HS injuries (or the equivalent anesthesia time point in sham animals) from mice anesthetized with 4% isoflurane and euthanized by transcardial perfusion with 50 ml of ice-cold heparinized saline. Brains were removed and divided into ipsilateral and contralateral hemispheres. Cortices and hippocampi were dissected and snap frozen in liquid nitrogen, and all samples were stored at −80°C until later use.
Assessment of Antioxidant Status and Markers of Oxidative Stress
Brain samples were obtained according to methods described above at 24 h after injury from 21 mice randomized to each of the aforementioned four groups (n = 5 each from sham RA, sham oxygenation, and combined CCI plus HS and RA, and n = 6 from combined CCI plus HS and oxygenation) as well as from five naïve animals. According to methods previously reported by Belikova et al
the brain tissue samples were thawed on ice and homogenized using a Tissue Tearor (BioCold Scientific, Fenton, MO) in lysis buffer (tissue weight/volume ratio of 1:20) consisting of sodium chloride (0.1 M final concentration), Tris chloride (0.01 M final concentration), and Triton X (1%) at pH adjusted to 7.4. Homogenates were centrifuged at 1,000g
for 10 min and then divided into aliquots for measurement of protein, ascorbate, reduced glutathione, and superoxide dismutase (SOD) activity. Metaphosphoric acid was added to a final concentration of 5% (v/v) to the aliquots for ascorbate measurements, and all samples were stored at −80 °C until use.
At the time of the measurement of ascorbate, samples were thawed on ice and vortexed for 10 s every 2 min at least five times, and then centrifuged at 12,000g for 5 min at 4°C. The supernatant was collected into a microcentrifuge tube and the pH was adjusted to 7.0 using 10 M NaOH individually in each sample using pH paper. The volume of base required for the adjustment was recorded. Each sample was divided into two aliquots, each containing 0.1–0.6 mg/ml protein. To ensure the selectivity of the assay toward ascorbate, one of the aliquots (50 μl) was treated with 1 U of ascorbate oxidase for 40 min at room temperature. When all samples were ready, they (20 μl) were transferred onto a 96-well plate along with ascorbate standards (0–1.5 nM). After this, 130 μl of 4-([9-acridinecarbonyl]-amino)-2,2,6,6-tetramethylpiperidine-1-oxyl radical stock aliquots (23.1 μM in phosphate buffer) was added immediately using a multichannel pipette to each well, and samples were incubated for 40 min at room temperature in the dark and analyzed using a Packard Fusion Alpha Multifunctional Plate Reader (PerkinElmer Life Sciences, Boston, MA). Fluorescence was measured using a 390 ± 15-nm filter for excitation and a 460 ± 35-nm filter for emission. Fluorescence readings from the ascorbate oxidase–treated samples were subtracted from nontreated and normalized to protein (corrected for prior dilutions with metaphosphoric acid and NaOH). Samples were analyzed in triplicate.
A fluorescence-based assay using ThioGlo-1, a maleimide reagent (Sigma-Aldrich, St. Louis, MO) that produces a highly fluorescent adduct upon its reaction with sulfhydryl groups, was used to measure levels of low-molecular-weight thiols (LMWTs), reduced glutathione, and protein sulfhydryl groups according to methods described previously.29
The immediate fluorescence response upon addition of ThioGlo-1 to brain tissue homogenate (10–35 μg of protein) estimated the content of total LMWTs according to a standard curve. The fluorescence response after addition of glutathione peroxidase (1 U) and cumene hydroperoxide (100 μM) for 30 min to an aliquot of the same sample was then measured. Reduced glutathione levels were then determined by taking the difference between the fluorescence response of the original sample (LMWT) and the glutathione peroxidase–treated sample. Total protein sulfhydryl levels were determined by adding 4 mM sodium dodecyl sulfate to each LMWT sample and measuring the fluorescence response. A Packard Fusion Alpha Plate Reader was used to detect fluorescence at excitation and emission wavelengths of 388 and 500 nm, respectively. Samples were analyzed in triplicate.
SOD activity was measured by the cytochrome c
according to the methods described by Walson et al.29
Manganese SOD (MnSOD) was measured in the presence of 1 mM potassium cyanide to inhibit both copper–zinc SOD and extracellular SOD, whereas the total SOD activity was measured in the absence of potassium cyanide. Samples were analyzed in triplicate.
Assessment of Cytokine, Chemokine, and Growth Factor Levels
Cytokine, chemokine, and growth factor levels in brain samples obtained 24 h after injury were quantified with a multiplex microbead array assay using the MILLIPLEX MAP Mouse Cytokine/Chemokine kit (Millipore, Billerica, MA) according to the manufacturer’s instructions and previously described methods.31
Brain tissue supernatant from ipsilateral (injury side) and contralateral hippocampi and cortices from 20 mice randomized to each of the aforementioned four groups (sham RA, sham oxygenation, combined CCI plus HS and RA, combined CCI plus HS and oxygenation; n = 5 per group), as well as from four naïve mice, was evaluated for levels of 21 chemokines, cytokines, and growth factors that included the following: monocyte chemotactic protein-1, macrophage inflammatory protein-1α, keratinocyte-derived cytokine (KC), eotaxin, interferon-inducible protein-10, regulated upon activation normal T-cell expressed and secreted (RANTES), interleukin (IL)-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-12, IL-13, IL-17, interferon-γ, tumor necrosis factor-α, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF (GM-CSF), and vascular endothelial growth factor. Protein concentrations in the brain supernatants were determined with the BCA Protein kit (Thermo Scientific, Rockford, IL), and all chemokine, cytokine, and growth factor values were normalized.
A total of 18 mice (combined CCI plus HS and RA and combined CCI plus HS and oxygenation; n = 9 per group) were evaluated at 7 day after injury for hippocampal neuronal survival. The animals were anesthetized with 4% isoflurane and killed by transcardial perfusion fixation with ice-cold saline followed by 10% buffered formalin according to methods published previously.27
Brain tissue was fixed with 10% buffered formalin and embedded in paraffin. Five-micron-thick sections, 200 µm apart from bregma −1.86 to −2.26, were prepared from each brain and stained with hematoxylin and eosin (Thermo Fisher Scientific, Pittsburgh, PA). Hippocampal neuronal survival was quantified as linear density as the number of cells per 0.1 mm in CA1 and CA3 regions by an evaluator blinded to treatment group using a Nikon Eclipse E600 microscope (Melville, NY) and ImageJ software (National Institutes of Health, Bethesda, MD) as reported previously.27
Two-way repeated measures ANOVA (effects for group, time, and group × time) were used to analyze the physiologic parameters with two-tailed hypothesis testing. Post hoc testing using Bonferroni correction for multiple comparisons was performed when group effect differences were identified. Oxidative stress data were compared between groups using ANOVA with post hoc testing for multiple comparisons using the Tukey test. Cytokine levels were compared between groups using ANOVA with Student-Newman-Keuls post hoc testing for multiple comparisons. Cell counts were compared between RA and oxygen treatment groups using the Student t test. All data are provided as mean ± SEM. A difference of P < 0.05 was considered significant. SAS software (SAS Institute Inc., Cary, NC) was used for statistical analyses.
diagrams the number of animals used in each arm of the study as well as the variable measured. A total of 53 mice were included in the combined CCI plus HS model and resuscitated with either oxygen (n = 26) or room air (n = 27). A select number of mice from each treatment group (oxygen vs
. room air) were selected for measurement of ICP (n = 6 and n = 8, respectively) and PbtO2
(n = 4 in each group). At 24 h, mice were sacrificed for measurement of levels of oxidative stress and inflammatory markers. At 7 days, the surviving mice were sacrificed for histologic assessment. Additional mice sacrificed at 7 days for histologic analysis were the surviving mice who had ICP monitoring in the contralateral hemisphere.
was measured in hippocampus underlying the cortical contusion. The first measurement was obtained upon placement of the oxygen sensor probe immediately after the CCI injury and was 47.9 ± 4.8 mmHg on RA (overall mean for all mice in both groups, n = 8) in isoflurane-anesthetized mice (fig. 2
). A second reading was obtained 5 min later (34.3 ± 5.0 mmHg), after which HS was initiated immediately according to the above-described protocol. The addition of HS to the CCI injury reduced hippocampal PbtO2
to an average pressure of 9.2 ± 3.7 mmHg during the 35-min shock phase (overall phase mean for all mice in both groups), although the reduction to 9.2 ± 3.7 mmHg during the shock phase was not significantly different than PbtO2
values immediately after CCI (47.9 ± 4.8 mmHg) or 5 min after CCI (34.3 ± 5.0 mmHg). Randomization of mice to treatment with oxygen, however, produced a marked and significant increase in the average hippocampal PbtO2
levels compared to treatment with RA during the prehospital phase (average mean prehospital phase value, 106.5 ± 16.9 vs.
38.4 ± 5.4 mmHg, respectively; P
= 0.0327). During the hospital phase, the difference between the oxygen- and RA-treated groups was close to significant (average mean hospital phase value, 125.5 ± 17.4 vs.
45.2 ± 3.3 mmHg, respectively; P
= 0.0504) (fig. 2
Hyperoxic resuscitation resulted in highly significant differences in PaO2
during the prehospital and hospital phases compared to RA (P
< 0.05) (table 1
). There was a significant, albeit modest, decrease in pH in mice treated with oxygen versus
RA during the prehospital phase (n = 51; P
< 0.032) that likely resulted from the significant increase in PaCO2
during the prehospital and hospital phases in oxygenated versus
RA groups (P
< 0.001). As expected, blood lactate levels increased and the base deficit worsened during the shock phase, with similar recovery in both treatment groups during the prehospital and hospital phases (table 1
Fluid requirements to reach and maintain the target MAP (>70 mmHg) during the prehospital resuscitation phase were reduced by treatment with oxygen versus
RA (154 ± 6 vs.
176 ± 4 ml/kg, P
= 0.004, respectively) (fig. 3
; table 1
). Despite reduced fluid requirements, the mean MAP was higher in the oxygen-treated group, although the difference was not statistically significant when compared with the RA group (fig. 3
; table 1
). Similarly, the mean ICP was lower and resultant mean cerebral perfusion pressure was higher with hyperoxic resuscitation compared to RA; however, the group differences were again not significant (fig. 3
; table 1
Brain Antioxidant Status and Oxidative Stress
Brain antioxidant status and oxidative stress were assessed by measuring hippocampal and cortical ascorbate, LMWTs, reduced glutathione, and protein oxidation, as well as total SOD and MnSOD activity in samples ipsilateral and contralateral to the injury in mice at 24 h after combined CCI and HS. There was a significant decrease in ascorbate levels in hippocampus of mice resuscitated with oxygen versus
RA (ipsilateral combined CCI and HS and oxygenation vs.
combined CCI and HS and RA; −19.54 ± 3.20 vs
. −4.42 ± 1.90 nM/mg protein, respectively; P
< 0.001; contralateral combined CCI plus HS and oxygenation vs.
combined CCI and HS and RA; −11.61 ± 2.41 vs.
−1.19 ± 2.50 nM/mg protein, respectively; P
= 0.005) (fig. 4
). Ascorbate levels were 42.35 ± 3.76 and 46.63 ± 4.06 nM/mg protein in left (ipsilateral) and right (contralateral) hippocampi, respectively, in naïve controls. Although ipsilateral cortical ascorbate levels were lower in oxygen- versus
RA-treated mice, this difference was not statistically significant. LMWT levels were significantly increased in the ipsilateral hippocampus of mice resuscitated with RA (combined CCI plus HS and RA; 17.37 ± 2.46 NM/mg protein) compared to controls (naïve, sham RA, and sham oxygenated values were 13.59 ± 2.05, 14.79 ± 3.65, and 14.27 ± 1.25 nmol/mg protein, respectively; P
= 0.002), but not compared to animals resuscitated with oxygen (combined CCI plus HS and oxygenation, 14.32 ± 1.09 nM/mg protein) (fig. 5
). There were no differences between groups in LMWT levels in the contralateral hippocampus or either cortex. Reduced glutathione was greater in the ipsilateral hippocampus of naïve mice and injured animals treated with RA (combined CCI plus HS and RA) versus
both sham groups, but the difference between the oxygen and RA resuscitation groups was not significant (fig. 5
). There were no measured differences in cortical reduced glutathione levels across all groups. Protein oxidation was measured by assessing protein sulfhydryl levels in brain samples at 24 h after injury. There was no effect of hyperoxic resuscitation (vs.
RA) on the level of protein oxidation in ipsilateral or contralateral hippocampus and cortex. Finally, there was no significant difference in the activity of total SOD in the hippocampus or cortex in animals from any group. MnSOD activity was increased in the ipsilateral hippocampus of mice resuscitated with oxygen versus
naïve animals (combined CCI plus HS and oxygenation vs.
naïve, 3.92 ± 0.75 vs.
2.71 ± 0.22 U/mg protein, respectively; P
= 0.046), but not compared to RA resuscitation (combined CCI plus HS and RA, 2.96 ± 0.28 U/mg protein) (fig. 5
). MnSOD activity in the cortex was not different across groups. In summary, ascorbate levels in the hippocampus were significantly reduced in the oxygen- versus
RA-resuscitated group. There was no difference in cortical ascorbate levels in the oxygen versus
RA groups. There was also no effect of oxygen on the levels of LMWT, reduced glutathione, protein oxidation, or MnSOD activity in the hippocampus or cortex compared to RA in mice at 24 h after combined CCI and HS.
Brain Chemokine, Cytokine, and Growth Factor Response
Assessment of chemokines, cytokines, and growth factors revealed a number of significant findings with regard to the effect of combined CCI and HS and the impact of treatment with supplemental oxygen.
Six chemokines were assessed, including monocyte chemotactic protein-1α, macrophage inflammatory protein-1, KC, eotaxin, interferon inducible protein-10, and RANTES. All six chemokines were significantly increased in injured hippocampus versus either naïve or sham groups (fig. 6
). The only difference between oxygen and RA treatment groups was for the chemokine KC, with significantly higher levels seen in hippocampus after hyperoxia. In the injured cortex, five of the six chemokines (all except RANTES) were significantly increased versus either naïve or sham groups. The magnitude of the increase in cortex was similar to that seen in hippocampus. The only difference between treatment groups in the cortex, however, was a significant increase in KC with RA compared with the hyperoxia group. Overall, chemokines were robustly increased in brain at 24 h after combined CCI plus HS, but KC was the only chemokine affected by hyperoxia versus RA treatment with opposite responses to oxygen in the hippocampus (increased) and cortex (decreased).
Twelve cytokines were assessed, including tumor necrosis factor-α, interferon-γ, IL-1β, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-12, IL-13, and IL-17. In hippocampus, five cytokines were increased after injury versus either naïve or sham groups (i.e., IL-1β, IL-2, IL-5, IL-6, and IL-17) (fig. 7
). IL-1β was significantly increased in hippocampus of both treatment groups. IL-2 and IL-6 were significantly increased in hippocampus only in the oxygenated group, whereas IL-5 and IL-17 were significantly increased in hippocampus only in the RA group. In cortex, only three cytokines were significantly increased versus either naïve or sham groups, namely, IL-4, IL-5, and IL-6. Of these three cytokines, increases in IL-4 and IL-5 were seen after injury only in the RA group. There was no significant difference in cortical IL-6 levels with regard to oxygen or RA treatment. The overall effects of oxygen on cytokine expression was an increase in hippocampal IL-2 and IL-6, whereas hippocampal IL-5 and IL-17 and cortical IL-4 and IL-5 were decreased when compared with RA treatment. Thus, the patterns of increase with these cytokines were highly region and treatment dependent.
Three growth factors were assessed, including G-CSF, GM-CSF, and vascular endothelial growth factor (VEGF) (fig. 8
). In hippocampus, G-CSF was significantly increased in hippocampus after injury versus either naïve or sham groups (fig. 8
). The increase in hippocampal G-CSF was greater in the oxygen group compared with the RA group. GM-CSF and VEGF were not significantly increased in hippocampus after combined CCI and HS injury. In cortex, G-CSF and VEGF were significantly increased after injury versus either naïve or sham groups. The increase in cortical VEGF after CCI and HS was significantly greater in the RA versus oxygen group; however, there was no observed effect of oxygen on cortical G-CSF versus RA. GM-CSF in cortex was not increased versus naïve or sham after combined CCI plus HS. The overall effect of oxygen on the growth factors after combined CCI plus HS injury was an increase in hippocampal G-CSF and decrease in cortical VEGF compared with RA treatment.
Surviving neurons in the selectively vulnerable CA1 and CA3 hippocampal regions underlying the cortical contusion were quantified in hematoxylin and eosin–stained sections at 7 days after combined CCI and HS and resuscitation. There was a significantly greater number of surviving neurons in the CA3 region of mice resuscitated with oxygen versus
RA (21 ± 2 vs.
15 ± 2 CA3 cells per 0.1-mm linear density, respectively; P
< 0.032) (fig. 9
). There was also a trend toward improved survival of CA1 neurons in the oxygenated group; however, the difference from RA was not significant (P
Hyperoxic resuscitation after combined CCI and HS in mice reduced fluid requirements and attenuated CA3 hippocampal neuronal death, a vulnerable brain region in our model, despite an increase in oxidative stress as evidenced by ascorbate depletion and a shift toward a more proinflammatory cytokine profile in brain versus
RA. Contrary to the recent concern with oxygen administration after cardiac arrest, combined CCI and HS represents a scenario where supplemental oxygen is beneficial. Our data mirror those in studies of stroke.15–22
Evidence also supports titration of therapies to maintain PbtO2
above a critical threshold after severe TBI,9
although the threshold remains undefined.38
Similarly, work in TBI suggests that hyperbaric oxygen may have merit,40
although further study is needed.
We used a mouse model coupling CCI with a pressure-controlled HS followed by MAP-targeted resuscitation. This mimics the prehospital scenario where supplemental oxygen can be provided as recommended by guidelines for prehospital treatment of severe TBI,41
taking into account that the guidelines do not recommend tracheal intubation if hypoxia can be corrected. Administration of pure oxygen via
nose cone revealed a greater than threefold increase in the PaO2
and PbtO2 versus
RA. The significantly increased PaO2
levels achieved with oxygen versus
RA permitted direct comparison. We were surprised by the robust PbtO2
response to oxygen, considering that the additional oxygen is in the dissolved form.
We found that oxygen use after combined CCI and HS in our model reduced resuscitation fluid requirements to reach the target MAP (70 mmHg) during the prehospital phase. Oxygen supplementation increases systemic vascular resistance, mostly because of a hyperoxia-induced decrease in nitric oxide availability.42–47
Increased systemic vascular resistance is balanced by a decrease in cardiac output secondary to a reflex decrease in heart rate.48
In shock states, hyperoxia stabilizes hemodynamics and redistributes blood flow to vital organs.49–51
Our results showed that despite reduced fluid volumes, oxygen administration increased mean MAP versus
RA, although the difference in MAP was not significant. Our approach to set a target MAP mimics the clinical scenario where caregivers desire to optimize cerebral perfusion pressure during resuscitation to minimize secondary injury.52
Hyperoxia is not a universal vasoconstrictor; its effects vary according to the vascular bed and the disease state.53
Breathing 100% oxygen causes cerebral vasoconstriction that is offset by an increase in PbtO2
from increased oxygen delivery.8
Normobaric oxygen administration in patients with severe TBI improves ICP and cerebral metabolism.11
We noted that oxygen administration in mice yielded a lower mean ICP and increased mean cerebral perfusion pressure after combined CCI and HS; however, these differences were not statistically different from RA treatment.
During resuscitation, pH decreased and PaCO2
increased in mice treated with oxygen versus
RA. The hyperoxia-induced decrease in pH and increase in PaCO2
likely resulted from suppression of the oxygen chemoreflex ventilatory drive.55
We did not measure respiratory rate; however, we measured the ventilatory response to oxygen in separate uninjured isoflurane-anesthetized mice and found a decreased respiratory rate versus
RA (data not shown). Increased PaCO2
likely resulted from decreased ventilation in the oxygen group as reported in TBI8
It is intriguing in our study that we observed a lower but not statistically different mean ICP during resuscitation with oxygen versus
RA despite a higher PaCO2
Ascorbate is depleted and brain antioxidant reserves are decreased after TBI.57
Consistent with our hypothesis, hyperoxia further compromised this brain antioxidant defense after combined CCI and HS versus
RA. Ascorbate decreased in the hippocampus underlying and contralateral to the cortical contusion at 24 h in mice resuscitated with oxygen. Ascorbate is the first line of defense against oxidative stress, and reduced levels represent a sensitive marker of oxidative injury.58
The decrease in hippocampal ascorbate with hyperoxia is significant but may be within the tolerance limits of the brain; thus, improvement in hippocampal neuronal survival is the most important result of resuscitation with oxygen versus
RA. The neuroprotective effects of oxygen resuscitation might be further improved by combination of 100% oxygen with an antioxidant in combined CCI and HS. We did not find a significant loss of ascorbate in the cortex, although there was a lower mean cortical ascorbate with oxygen treatment versus
RA. The cortex is severely injured after the level of CCI imposed, possibly limiting perfusion and oxygen exposure; we did not measure cortical PbtO2
. In terms of markers of oxidative stress, we did not observe differences in levels of reduced glutathione, LMWT, or SOD after resuscitation with oxygen versus
RA. It may be that the effect of hyperoxia on brain antioxidant reserves is not as severe as anticipated, or that the duration of oxygen exposure was short. We observed an increase in MnSOD activity in the injured hippocampus of mice resuscitated with oxygen versus
naïve, but not versus
RA. MnSOD is the first line of defense against superoxide in mitochondria and is induced after TBI.60
Increased MnSOD activity in injured hippocampus is interesting given our prior report showing inactivation of MnSOD by neuronal nitric oxide synthase–mediated nitration after TBI.61
TBI plus HS likely represents a unique insult.
This study builds on our prior report showing robust inflammation after combined CCI and HS in mice dominated by chemokines and selective increases in cytokines and growth factors.32
We assessed hippocampal and cortical tissue in the injured hemisphere, where changes in these mediators are likely to define the impact of oxygen administration. Chemokines represent the predominant inflammatory mediator class after combined CCI and HS in mouse brain and signal cellular infiltration.61–67
Because oxygen reduced neuronal death but increased oxidative stress, one could not a priori
suggest that oxygen would exacerbate or attenuate neuroinflammation, despite links between leukocyte infiltration, inflammatory mediators, tissue injury, and oxidative stress.61
Consistent with our previous work,32
there was a robust increase in chemokine levels after combined CCI and HS, although oxygen did not consistently increase chemokines to reflect an exacerbation of neuroinflammation. Effects of oxygen on cytokines, however, produced significant effects that are predominantly proinflammatory. Overall, the effect of oxygen on cytokine expression was an increase in hippocampal IL-2 and IL-6, whereas hippocampal IL-5 and IL-17 and cortical IL-4 and IL-5 were decreased versus
RA. IL-6 and IL-1β are important signaling molecules after TBI, with IL-6 consistently increased in brain such that it is considered a TBI biomarker.69
Thus, whether hyperoxia-induced augmentation of increased IL-6 in injured hippocampus after combined CCI and HS is beneficial or detrimental is unclear. Given that IL-6 overexpression is neurotoxic,71
it suggests a proinflammatory effect of hyperoxia. IL-1β is also implicated in signaling proinflammatory events and the up-regulation of tropic factors after TBI.72–76
However, oxygen did not influence IL-1β. Supplemental oxygen blunted increases in IL-4, IL-5, and IL-17 in injured cortex and/or hippocampus. IL-4 plays an antiinflammatory Th2 role in TBI,76
possibly by triggering a neuroprotective profile in microglia,78
and IL-5 has Th2 antiinflammatory effects.79
IL-17 may mediate regeneration.80
Thus, our findings also suggest a proinflammatory effect of supplemental oxygen—reducing antiinflammatory cytokines. However, IL-17 also mediates a proinflammatory Th17 response in brain, exacerbating injury.80–82
Increases in IL-2 in hippocampus were also magnified by oxygen; IL-2 is a proinflammatory cytokine important for Th1 signaling.
Finally, oxygen blunted the cortical VEGF response after combined CCI and HS. Given the important role of tissue hypoxia in VEGF signaling and the marked increase in PbtO2 by oxygen in our model, this is not surprising. The impact of this finding, however, is unclear and could reflect either a reduction in damage or attenuation of vascular regeneration signaling.
Despite increased evidence of oxidative stress in brain, oxygen administration after combined CCI and HS attenuated hippocampal CA3 neuronal death at 7 days after injury. The moderate CCI we used was designed to leave the hippocampus intact but vulnerable to HS.33
We were surprised to see benefit from oxygen on CA3 rather than CA1, as we propose that the entire hippocampus underlying the cortical injury represents a penumbra. We observed a positive trend in CA1 cell counts with oxygen treatment; a larger sample size is needed to test our hypothesis in CA1.27
TBI increases metabolic demands in CA3, making it vulnerable to secondary injury, which might benefit from oxygen during hypotension.83
Thus, TBI plus HS may show beneficial and detrimental effects of supplementation oxygen. This is similar to stroke, where benefit was seen during occlusion but detrimental effects occurred during reperfusion.84
Our study has limitations. TBI plus HS is a complex scenario with limitless severity levels. We used a single injury level, a single level of HS; thus, the findings could depend on the clinical presentation. Nevertheless, our model includes a clinically relevant injury and resuscitation. We administered pure oxygen to maximize the potential effect of hyperoxia, but it is unclear what affect titration of the fraction of inspired oxygen would have. We also studied only adult male mice, which are more vulnerable to oxidative stress than female mice.85
Studies of behavioral and long-term outcomes are also needed.
Given the controversy regarding supplemental oxygen use after cardiac arrest, stroke, and TBI, we sought to determine whether oxygen influenced resuscitation and neuropathologic outcome in TBI plus HS. Hyperoxia improved cerebral hemodynamics and CA3 hippocampal neuron survival but worsened oxidative stress versus RA and possibly increased inflammation. The overall benefit of hyperoxic resuscitation suggests the need to test the addition of an antioxidant strategy to supplemental oxygen or other approaches to enhance oxygen delivery after TBI plus HS injuries.
1. Chesnut RM, Marshall LF, Klauber MR, Blunt BA, Baldwin N, Eisenberg HM, Jane JA, Marmarou A, Foulkes MA. The role of secondary brain injury in determining outcome from severe head injury. J Trauma. 1993;34:216–22
2. Nelson TJ, Wall DB, Stedje-Larsen ET, Clark RT, Chambers LW, Bohman HR. Predictors of mortality in close proximity blast injuries during Operation Iraqi Freedom. J Am Coll Surg. 2006;202:418–22
3. Chesnut RM, Marshall SB, Piek J, Blunt BA, Klauber MR, Marshall LF. Early and late systemic hypotension as a frequent and fundamental source of cerebral ischemia following severe brain injury in the Traumatic Coma Data Bank. Acta Neurochir Suppl (Wien). 1993;59:121–5
4. Adelson PD, Srinivas R, Chang Y, Bell M, Kochanek PM. Cerebrovascular response in children following severe traumatic brain injury. Childs Nerv Syst. 2011;27:1465–76
5. Marion DW, Darby J, Yonas H. Acute regional cerebral blood flow changes caused by severe head injuries. J Neurosurg. 1991;74:407–14
6. Bouma GJ, Muizelaar JP, Stringer WA, Choi SC, Fatouros P, Young HF. Ultra-early evaluation of regional cerebral blood flow in severely head-injured patients using xenon-enhanced computerized tomography. J Neurosurg. 1992;77:360–8
7. Bouma GJ, Muizelaar JP, Choi SC, Newlon PG, Young HF. Cerebral circulation and metabolism after severe traumatic brain injury: The elusive role of ischemia. J Neurosurg. 1991;75:685–93
8. Rangel-Castilla L, Lara LR, Gopinath S, Swank PR, Valadka A, Robertson C. Cerebral hemodynamic effects of acute hyperoxia and hyperventilation after severe traumatic brain injury. J Neurotrauma. 2010;27:1853–63
9. Valadka AB, Gopinath SP, Contant CF, Uzura M, Robertson CS. Relationship of brain tissue PO2 to outcome after severe head injury. Crit Care Med. 1998;26:1576–81
10. Magnoni S, Ghisoni L, Locatelli M, Caimi M, Colombo A, Valeriani V, Stocchetti N. Lack of improvement in cerebral metabolism after hyperoxia in severe head injury: A microdialysis study. J Neurosurg. 2003;98:952–8
11. Tolias CM, Reinert M, Seiler R, Gilman C, Scharf A, Bullock MR. Normobaric hyperoxia–induced improvement in cerebral metabolism and reduction in intracranial pressure in patients with severe head injury: A prospective historical cohort-matched study. J Neurosurg. 2004;101:435–44
12. Tisdall MM, Tachtsidis I, Leung TS, Elwell CE, Smith M. Increase in cerebral aerobic metabolism by normobaric hyperoxia after traumatic brain injury. J Neurosurg. 2008;109:424–32
13. Diringer MN, Aiyagari V, Zazulia AR, Videen TO, Powers WJ. Effect of hyperoxia on cerebral metabolic rate for oxygen measured using positron emission tomography in patients with acute severe head injury. J Neurosurg. 2007;106:526–9
14. Kochanek PM, Bayir H. Titrating oxygen during and after cardiopulmonary resuscitation. JAMA. 2010;303:2190–1
15. Flynn EP, Auer RN. Eubaric hyperoxemia and experimental cerebral infarction. Ann Neurol. 2002;52:566–72
16. Singhal AB, Dijkhuizen RM, Rosen BR, Lo EH. Normobaric hyperoxia reduces MRI diffusion abnormalities and infarct size in experimental stroke. Neurology. 2002;58:945–52
17. Singhal AB, Wang X, Sumii T, Mori T, Lo EH. Effects of normobaric hyperoxia in a rat model of focal cerebral ischemia-reperfusion. J Cereb Blood Flow Metab. 2002;22:861–8
18. Kim HY, Singhal AB, Lo EH. Normobaric hyperoxia extends the reperfusion window in focal cerebral ischemia. Ann Neurol. 2005;57:571–5
19. Liu S, Liu W, Ding W, Miyake M, Rosenberg GA, Liu KJ. Electron paramagnetic resonance-guided normobaric hyperoxia treatment protects the brain by maintaining penumbral oxygenation in a rat model of transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2006;26:1274–84
20. Shin HK, Dunn AK, Jones PB, Boas DA, Lo EH, Moskowitz MA, Ayata C. Normobaric hyperoxia improves cerebral blood flow and oxygenation, and inhibits peri-infarct depolarizations in experimental focal ischaemia. Brain. 2007;130(Pt 6):1631–42
21. Singhal AB, Ratai E, Benner T, Vangel M, Lee V, Koroshetz WJ, Schaefer PW, Sorensen AG, Gonzalez RG. Magnetic resonance spectroscopy study of oxygen therapy in ischemic stroke. Stroke. 2007;38:2851–4
22. Singhal AB, Benner T, Roccatagliata L, Koroshetz WJ, Schaefer PW, Lo EH, Buonanno FS, Gonzalez RG, Sorensen AG. A pilot study of normobaric oxygen therapy in acute ischemic stroke. Stroke. 2005;36:797–802
23. Liu Y, Rosenthal RE, Haywood Y, Miljkovic-Lolic M, Vanderhoek JY, Fiskum G. Normoxic ventilation after cardiac arrest reduces oxidation of brain lipids and improves neurological outcome. Stroke. 1998;29:1679–86
24. Kilgannon JH, Jones AE, Shapiro NI, Angelos MG, Milcarek B, Hunter K, Parrillo JE, Trzeciak SEmergency Medicine Shock Research Network (EMShockNet) Investigators. . Association between arterial hyperoxia following resuscitation from cardiac arrest and in-hospital mortality. JAMA. 2010;303:2165–71
25. Vereczki V, Martin E, Rosenthal RE, Hof PR, Hoffman GE, Fiskum G. Normoxic resuscitation after cardiac arrest protects against hippocampal oxidative stress, metabolic dysfunction, and neuronal death. J Cereb Blood Flow Metab. 2006;26:821–35
26. Hazelton JL, Balan I, Elmer GI, Kristian T, Rosenthal RE, Krause G, Sanderson TH, Fiskum G. Hyperoxic reperfusion after global cerebral ischemia promotes inflammation and long-term hippocampal neuronal death. J Neurotrauma. 2010;27:753–62
27. Hemerka JN, Wu X, Dixon CE, Garman RH, Exo JL, Shellington DK, Blasiole B, Vagni VA, Janesko-Feldman K, Xu M, Wisniewski SR, Bayır H, Jenkins LW, Clark RS, Tisherman SA, Kochanek PM. Severe brief pressure-controlled hemorrhagic shock after traumatic brain injury exacerbates functional deficits and long-term neuropathological damage in mice. J Neurotrauma. 2012;29:2192–208
28. Belikova NA, Glumac AL, Kapralova V, Cheikhi A, Tyurina YY, Vagni VA, Kochanek PM, Kagan VE, Bayir H. A high-throughput screening assay of ascorbate in brain samples. J Neurosci Methods. 2011;201:185–90
29. Walson KH, Tang M, Glumac A, Alexander H, Manole MD, Ma L, Hsia CJ, Clark RS, Kochanek PM, Kagan VE, Bayr H. Normoxic versus hyperoxic resuscitation in pediatric asphyxial cardiac arrest: Effects on oxidative stress. Crit Care Med. 2011;39:335–43
30. McCord JM, Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem. 1969;244:6049–55
31. Tang M, Alexander H, Clark RS, Kochanek PM, Kagan VE, Bayir H. Minocycline reduces neuronal death and attenuates microglial response after pediatric asphyxial cardiac arrest. J Cereb Blood Flow Metab. 2010;30:119–29
32. Shein SL, Shellington DK, Jackson EK, Bayır H, Clark RSB, Jenkins LW, Dixon CE, Janesko-Feldman K, Vagni VA, Kochanek PM. Impact of hemorrhagic shock on the inflammatory response to experimental traumatic brain injury. Crit Care Med. 2011;38(suppl):A144
33. Dennis AM, Haselkorn ML, Vagni VA, Garman RH, Janesko-Feldman K, Bayir H, Clark RS, Jenkins LW, Dixon CE, Kochanek PM. Hemorrhagic shock after experimental traumatic brain injury in mice: Effect on neuronal death. J Neurotrauma. 2009;26:889–99
34. Shellington DK, Du L, Wu X, Exo J, Vagni V, Ma L, Janesko-Feldman K, Clark RS, Bayir H, Dixon CE, Jenkins LW, Hsia CJ, Kochanek PM. Polynitroxylated pegylated hemoglobin: A novel neuroprotective hemoglobin for acute volume-limited fluid resuscitation after combined traumatic brain injury and hemorrhagic hypotension in mice. Crit Care Med. 2011;39:494–505
35. Exo JL, Shellington DK, Bayir H, Vagni VA, Janesco-Feldman K, Ma L, Hsia CJ, Clark RS, Jenkins LW, Dixon CE, Kochanek PM. Resuscitation of traumatic brain injury and hemorrhagic shock with polynitroxylated albumin, hextend, hypertonic saline, and lactated Ringer’s: Effects on acute hemodynamics, survival, and neuronal death in mice. J Neurotrauma. 2009;26:2403–8
36. Spiotta AM, Stiefel MF, Gracias VH, Garuffe AM, Kofke WA, Maloney-Wilensky E, Troxel AB, Levine JM, Le Roux PD. Brain tissue oxygen-directed management and outcome in patients with severe traumatic brain injury. J Neurosurg. 2010;113:571–80
37. Narotam PK, Morrison JF, Nathoo N. Brain tissue oxygen monitoring in traumatic brain injury and major trauma: Outcome analysis of a brain tissue oxygen-directed therapy. J Neurosurg. 2009;111:672–82
38. Figaji AA, Zwane E, Graham Fieggen A, Argent AC, Le Roux PD, Peter JC. The effect of increased inspired fraction of oxygen on brain tissue oxygen tension in children with severe traumatic brain injury. Neurocrit Care. 2010;12:430–7
39. Vilalta A, Sahuquillo J, Merino MA, Poca MA, Garnacho A, Martínez-Valverde T, Dronavalli M. Normobaric hyperoxia in traumatic brain injury: Does brain metabolic state influence the response to hyperoxic challenge? J Neurotrauma. 2011;28:1139–48
40. Rockswold SB, Rockswold GL, Zaun DA, Zhang X, Cerra CE, Bergman TA, Liu J. A prospective, randomized clinical trial to compare the effect of hyperbaric to normobaric hyperoxia on cerebral metabolism, intracranial pressure, and oxygen toxicity in severe traumatic brain injury. J Neurosurg. 2010;112:1080–94
41. Badjatia N, Carney N, Crocco TJ, Fallat ME, Hennes HM, Jagoda AS, Jernigan S, Letarte PB, Lerner EB, Moriarty TM, Pons PT, Sasser S, Scalea T, Schleien CL, Wright DWBrain Trauma Foundation; BTF Center for Guidelines Management. . Guidelines for prehospital management of traumatic brain injury 2nd edition. Prehosp Emerg Care. 2008;12(suppl 1):S1–52
42. Benedict FG, Higgins HL. Effects on men at rest of breathing oxygen-rich gas mixtures. Am J Physiol. 1911;28:1–28
43. Whitehorn WV, Edelmann A, Hitchcock FA. The cardiovascular responses to the breathing of 100 per cent oxygen at normal barometric pressure. Am J Physiol. 1946;146:61–5
44. Eggers G, Paley H, Leonard J, Warren J. Hemodynamic responses to oxygen breathing in man. J Appl Physiol. 1962;17:75–9
45. Milone SD, Newton GE, Parker JD. Hemodynamic and biochemical effects of 100% oxygen breathing in humans. Can J Physiol Pharmacol. 1999;77:124–30
46. Pasgaard T, Stankevicius E, Jørgensen MM, Ostergaard L, Simonsen U, Frøbert O. Hyperoxia reduces basal release of nitric oxide and contracts porcine coronary arteries. Acta Physiol (Oxf). 2007;191:285–96
47. Stamler JS, Jia L, Eu JP, McMahon TJ, Demchenko IT, Bonaventura J, Gernert K, Piantadosi CA. Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient. Science. 1997;276:2034–7
48. Daly WJ, Bondurant S. Effects of oxygen breathing on the heart rate, blood pressure, and cardiac index of normal men: Resting, with reactive hyperemia, and after atropine. J Clin Invest. 1962;46:1617–24
49. Bitterman H, Brod V, Weisz G, Kushnir D, Bitterman N. Effects of oxygen on regional hemodynamics in hemorrhagic shock. Am J Physiol. 1996;271(1 Pt 2):H203–11
50. Sukhotnik I, Krausz MM, Brod V, Balan M, Turkieh A, Siplovich L, Bitterman H. Divergent effects of oxygen therapy in four models of uncontrolled hemorrhagic shock. Shock. 2002;18:277–84
51. Waisman D, Brod V, Wolff R, Sabo E, Chernin M, Weintraub Z, Rotschild A, Bitterman H. Effects of hyperoxia on local and remote microcirculatory inflammatory response after splanchnic ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2003;285:H643–52
52. DeWitt DS, Prough DS. Blast-induced brain injury and posttraumatic hypotension and hypoxemia. J Neurotrauma. 2009;26:877–87
53. Rousseau A, Bak Z, Janerot-Sjöberg B, Sjöberg F. Acute hyperoxaemia-induced effects on regional blood flow, oxygen consumption and central circulation in man. Acta Physiol Scand. 2005;183:231–40
54. Floyd TF, Clark JM, Gelfand R, Detre JA, Ratcliffe S, Guvakov D, Lambertsen CJ, Eckenhoff RG. Independent cerebral vasoconstrictive effects of hyperoxia and accompanying arterial hypocapnia at 1 ATA. J Appl Physiol. 2003;95:2453–61
55. Dejours P. Chemoreflexes in breathing. Physiol Rev. 1962;42:335–58
56. Atkins JL, Johnson KB, Pearce FJ. Cardiovascular responses to oxygen inhalation after hemorrhage in anesthetized rats: Hyperoxic vasoconstriction. Am J Physiol Heart Circ Physiol. 2007;292:H776–85
57. Tyurin VA, Tyurina YY, Borisenko GG, Sokolova TV, Ritov VB, Quinn PJ, Rose M, Kochanek P, Graham SH, Kagan VE. Oxidative stress following traumatic brain injury in rats: Quantitation of biomarkers and detection of free radical intermediates. J Neurochem. 2000;75:2178–89
58. Bayir H, Kagan VE, Tyurina YY, Tyurin V, Ruppel RA, Adelson PD, Graham SH, Janesko K, Clark RS, Kochanek PM. Assessment of antioxidant reserves and oxidative stress in cerebrospinal fluid after severe traumatic brain injury in infants and children. Pediatr Res. 2002;51:571–8
59. Bayir H, Kagan VE, Borisenko GG, Tyurina YY, Janesko KL, Vagni VA, Billiar TR, Williams DL, Kochanek PM. Enhanced oxidative stress in iNOS-deficient mice after traumatic brain injury: Support for a neuroprotective role of iNOS. J Cereb Blood Flow Metab. 2005;25:673–84
60. Sullivan PG, Bruce-Keller AJ, Rabchevsky AG, Christakos S, Clair DK, Mattson MP, Scheff SW. Exacerbation of damage and altered NF-kappaB activation in mice lacking tumor necrosis factor receptors after traumatic brain injury. J Neurosci. 1999;19:6248–56
61. Bayir H, Kagan VE, Clark RS, Janesko-Feldman K, Rafikov R, Huang Z, Zhang X, Vagni V, Billiar TR, Kochanek PM. Neuronal NOS-mediated nitration and inactivation of manganese superoxide dismutase in brain after experimental and human brain injury. J Neurochem. 2007;101:168–81
62. Clark RS, Schiding JK, Kaczorowski SL, Marion DW, Kochanek PM. Neutrophil accumulation after traumatic brain injury in rats: Comparison of weight drop and controlled cortical impact models. J Neurotrauma. 1994;11:499–506
63. Carlos TM, Clark RS, Franicola-Higgins D, Schiding JK, Kochanek PM. Expression of endothelial adhesion molecules and recruitment of neutrophils after traumatic brain injury in rats. J Leukoc Biol. 1997;61:279–85
64. Foley LM, Hitchens TK, Ho C, Janesko-Feldman KL, Melick JA, Bayir H, Kochanek PM. Magnetic resonance imaging assessment of macrophage accumulation in mouse brain after experimental traumatic brain injury. J Neurotrauma. 2009;26:1509–19
65. Mills PH, Hitchens TK, Foley LM, Link T, Ye Q, Weiss CR, Thompson JD, Gilson WD, Arepally A, Melick JA, Kochanek PM, Ho C, Bulte JW, Ahrens ET. Automated detection and characterization of SPIO-labeled cells and capsules using magnetic field perturbations. Magn Reson Med. 2012;67:278–89
66. Morganti-Kossmann MC, Satgunaseelan L, Bye N, Kossmann T. Modulation of immune response by head injury. Injury. 2007;38:1392–400
67. Otto VI, Stahel PF, Rancan M, Kariya K, Shohami E, Yatsiv I, Eugster HP, Kossmann T, Trentz O, Morganti-Kossmann MC. Regulation of chemokines and chemokine receptors after experimental closed head injury. Neuroreport. 2001;12:2059–64
68. Koedel U, Merbt UM, Schmidt C, Angele B, Popp B, Wagner H, Pfister HW, Kirschning CJ. Acute brain injury triggers MyD88-dependent, TLR2/4-independent inflammatory responses. Am J Pathol. 2007;171:200–13
69. Kossmann T, Hans VH, Imhof HG, Stocker R, Grob P, Trentz O, Morganti-Kossmann C. Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe traumatic brain injuries. Shock. 1995;4:311–7
70. Bell MJ, Kochanek PM, Doughty LA, Carcillo JA, Adelson PD, Clark RS, Wisniewski SR, Whalen MJ, DeKosky ST. Interleukin-6 and interleukin-10 in cerebrospinal fluid after severe traumatic brain injury in children. J Neurotrauma. 1997;14:451–7
71. Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MB, Mucke L. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci USA. 1993;90:10061–5
72. Toulmond S, Rothwell NJ. Interleukin-1 receptor antagonist inhibits neuronal damage caused by fluid percussion injury in the rat. Brain Res. 1995;671:261–6
73. DeKosky ST, Styren SD, O’Malley ME, Goss JR, Kochanek P, Marion D, Evans CH, Robbins PD. Interleukin-1 receptor antagonist suppresses neurotrophin response in injured rat brain. Ann Neurol. 1996;39:123–7
74. Marion DW, Penrod LE, Kelsey SF, Obrist WD, Kochanek PM, Palmer AM, Wisniewski SR, DeKosky ST. Treatment of traumatic brain injury with moderate hypothermia. N Engl J Med. 1997;336:540–6
75. Buttram SD, Wisniewski SR, Jackson EK, Adelson PD, Feldman K, Bayir H, Berger RP, Clark RS, Kochanek PM. Multiplex assessment of cytokine and chemokine levels in cerebrospinal fluid following severe pediatric traumatic brain injury: Effects of moderate hypothermia. J Neurotrauma. 2007;24:1707–17
76. Amick JE, Yandora KA, Bell MJ, Wisniewski SR, Adelson PD, Carcillo JA, Janesko KL, DeKosky ST, Carlos TM, Clark RS, Kochanek PM. The Th1 versus Th2 cytokine profile in cerebrospinal fluid after severe traumatic brain injury in infants and children. Pediatr Crit Care Med. 2001;2:260–4
77. Dalgard CL, Cole JT, Kean WS, Lucky JJ, Sukumar G, McMullen DC, Pollard HB, Watson WD. The cytokine temporal profile in rat cortex after controlled cortical impact. Front Mol Neurosci. 2012;5:6
78. Zhao W, Xie W, Xiao Q, Beers DR, Appel SH. Protective effects of an anti-inflammatory cytokine, interleukin-4, on motoneuron toxicity induced by activated microglia. J Neurochem. 2006;99:1176–87
79. Nygårdas M, Aspelin C, Paavilainen H, Röyttä M, Waris M, Hukkanen V. Treatment of experimental autoimmune encephalomyelitis in SJL/J mice with a replicative HSV-1 vector expressing interleukin-5. Gene Ther. 2011;18:646–55
80. Li Z, Burns AR, Han L, Rumbaut RE, Smith CW. IL-17 and VEGF are necessary for efficient corneal nerve regeneration. Am J Pathol. 2011;178:1106–16
81. Zhao D, Hou N, Cui M, Liu Y, Liang X, Zhuang X, Zhang Y, Zhang L, Yin D, Gao L, Zhang Y, Ma C. Increased T cell immunoglobulin and mucin domain 3 positively correlate with systemic IL-17 and TNF-α level in the acute phase of ischemic stroke. J Clin Immunol. 2011;31:719–27
82. Jadidi-Niaragh F, Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand J Immunol. 2011;74:1–13
83. Zanier ER, Lee SM, Vespa PM, Giza CC, Hovda DA. Increased hippocampal CA3 vulnerability to low-level kainic acid following lateral fluid percussion injury. J Neurotrauma. 2003;20:409–20
84. Rink C, Roy S, Khan M, Ananth P, Kuppusamy P, Sen CK, Khanna S. Oxygen-sensitive outcomes and gene expression in acute ischemic stroke. J Cereb Blood Flow Metab. 2010;30:1275–87
85. Bayir H, Marion DW, Puccio AM, Wisniewski SR, Janesko KL, Clark RS, Kochanek PM. Marked gender effect on lipid peroxidation after severe traumatic brain injury in adult patients. J Neurotrauma. 2004;21:1–8
© 2013 American Society of Anesthesiologists, Inc.
Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.